Intellia Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The phase III HAELO trial showed that a single dose of lonvo-z, an in vivo CRISPR-based gene-editing therapy, led to an 87% reduction in HAE attack rates and 62% of patients being attack- and therapy-free at six months, with a favorable safety profile. Early crossover data suggest further improvements over time. Additional long-term data and subgroup analyses will be presented at EAACI.
-
Pivotal Phase III HAELO study data is expected mid-year, targeting a first-in-class in vivo gene editing launch next year. The product aims for high efficacy, durable attack-free outcomes, and strong commercial positioning, with a straightforward manufacturing process and significant cost-saving potential for healthcare systems.
-
lonvo-z for HAE is nearing Phase III completion with strong efficacy and safety, aiming for a 2027 U.S. launch. TTR programs have resumed after safety enhancements, and commercial preparations are underway for a high-margin, premium-priced product.
-
Late-stage programs for HAE and TTR amyloidosis show strong efficacy and safety, with Lombozi poised for a 2027 launch and Nexi aiming to resume phase 3 after resolving a clinical hold. Market and payer feedback is highly favorable, and the company is well-funded.
Fiscal Year 2025
-
Rapid progress in phase 3 trials for HAE and ATTR amyloidosis, with strong patient and physician interest in lonvo-z. Financials improved year-over-year, and commercial launch preparations are underway. MAGNITUDE-2 hold lifted, but MAGNITUDE remains on FDA hold pending further review.
-
A significant liver safety event in the MAGNITUDE phase III trial for Nex-Z led to a protocol-specified pause in dosing and screening, with the affected patient stable and under observation. The event is believed to be related to the TTR gene target, not the LNP platform, and does not impact the ongoing Lonvo-z HAELO study.
-
Exceeded clinical and operational goals in H1 2025, with accelerated phase III enrollment and strong interim data for lead programs. Cash runway extends into 2027, supporting expanded trials and commercial readiness.
-
The meeting covered board introductions, voting on six key proposals, and confirmation of a quorum. All proposals, including director elections, auditor ratification, executive compensation, and the 2025 Equity Incentive Plan, were approved. No questions were raised by stockholders.
-
Late-stage gene editing programs are advancing with accelerated enrollment and strong clinical momentum. ATTR and HAE studies target deep, durable responses, with pivotal data and commercial launches expected over the next 12–18 months. Over $700M in cash supports execution and growth.
-
Achieved key clinical milestones with rapid phase III enrollment in HAE and ATTR programs, maintained a strong cash position with a runway into 2027, and executed cost-saving restructuring. Regulatory progress and commercial readiness position the company for upcoming product launches.
-
The conference highlighted rapid progress in gene editing therapies, with robust phase three programs for ATTR cardiomyopathy and HAE. Deep TTR reduction and potential for functional cures set these therapies apart, while strong patient and physician demand contrasts with investor skepticism.
-
Profound TTR reduction and rapid patient response highlight strong clinical progress, with three launches targeted between 2027 and 2030. HAE program aims for a functional cure label, supported by durable data and high patient demand. Restructuring ensures financial runway into 2027.
-
Focused on ATTR and HAE, the company is advancing three Phase 3 programs, targeting commercial launches from 2027 to 2030. NTLA-2002 and Nex-Z show strong clinical promise and market potential, supported by efficient manufacturing and high physician interest.
Fiscal Year 2024
-
Strong progress in late-stage HAE and ATTR amyloidosis programs, with robust trial enrollment and positive clinical data supporting potential first-in-class gene editing therapies. Restructuring and focused investments are expected to reduce expenses and support commercial readiness for launches between 2027 and 2030.
-
Interim phase I data for Nexi in ATTR amyloidosis showed rapid, deep, and durable TTR reduction, with 80% of patients experiencing stability or improvement in key cardiac markers at 12 months. Safety was favorable, and results support ongoing phase III trials and the potential for best-in-class efficacy.
-
Substantial clinical and regulatory progress was made in Q3 2024, with positive Phase 2 HAE results, rapid advancement of late-stage ATTR amyloidosis and AATD programs, and a strong cash position to fund operations into late 2026.
-
A single 50 mg dose of NTLA-2002 in Phase 2 led to an 86% reduction in plasma kallikrein and up to 81% reduction in HAE attacks, with 73% of patients attack-free. The therapy was well-tolerated and is advancing to Phase 3 as a potential one-time, functional cure.
-
Substantial clinical progress was reported, with NTLA-2002 and NTLA-2001 advancing in pivotal trials and NTLA-3001 entering first-in-human studies. Financials remain strong, supporting operations into late 2026, while the company positions its gene editing therapies to address significant unmet needs in HAE, ATTR, and AATD.
-
The meeting introduced the board and executive team, presented four shareholder proposals, and confirmed all were approved, including director elections, auditor ratification, executive compensation, and a governance amendment limiting officer liability.
-
NTLA-2002 demonstrated a 98% reduction in HAE attacks and durable kallikrein suppression, with eight of ten patients attack-free and all off prophylaxis after a single dose. Safety was favorable, and strong patient enthusiasm supports rapid advancement to Phase II and III trials.